Summit Partners Public Asset Management LLC Takes Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Summit Partners Public Asset Management LLC purchased a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 550,737 shares of the company’s stock, valued at approximately $9,274,000. Summit Partners Public Asset Management LLC owned approximately 0.27% of Cellebrite DI as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. FMR LLC grew its position in shares of Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock worth $94,586,000 after purchasing an additional 3,239,307 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Cellebrite DI during the third quarter worth approximately $23,402,000. Pembroke Management LTD grew its position in Cellebrite DI by 104.9% during the second quarter. Pembroke Management LTD now owns 1,535,726 shares of the company’s stock worth $18,352,000 after buying an additional 786,310 shares in the last quarter. Meitav Investment House Ltd. increased its stake in Cellebrite DI by 29.7% during the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock worth $34,797,000 after acquiring an additional 473,293 shares during the period. Finally, Telemark Asset Management LLC acquired a new position in Cellebrite DI in the 3rd quarter valued at $6,736,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Down 0.2 %

Shares of NASDAQ:CLBT opened at $19.89 on Friday. Cellebrite DI Ltd. has a 52-week low of $7.91 and a 52-week high of $21.00. The company has a fifty day moving average of $18.17 and a 200-day moving average of $15.07.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period last year, the company earned $0.09 earnings per share. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on CLBT. Needham & Company LLC raised their price target on Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Craig Hallum boosted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Bank of America increased their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Lake Street Capital boosted their price objective on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has an average rating of “Buy” and a consensus target price of $20.29.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.